This study is not yet accepting patients
Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease
Summary
- Eligibility
- for people ages 12-35 (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Mark Walters, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Mark Walters, MD
The over-arching goal of my research career has been to develop and expand curative therapies for hemoglobin disorders in particular and non-malignant hematopoietic disorders more broadly. I have focused on genome editing approaches most recently, which rely upon modification of autologous hematopoietic cells to elicit a curative effect.
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Mark Walters, MD
- ID
- NCT04774536
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 9 study participants
- Last Updated